Sunshine Lake Pharma identifies new GTPase KRAS G12C inhibitors
Sunshine Lake Pharma Co. Ltd. has patented GTPase KRAS (G12C mutant) inhibitors found to be potentially useful for the treatment of cancer.
Sunshine Lake Pharma Co. Ltd. has patented GTPase KRAS (G12C mutant) inhibitors found to be potentially useful for the treatment of cancer.